American Journal of Roentgenology, Vol 171, 137-143, Copyright © 1998 by American Roentgen Ray Society

ARTICLES

Preclinical evaluation and phase I clinical trial of a 99mTc-labeled synthetic polymer used in blood pool imaging

RJ Callahan, A Bogdanov Jr, AJ Fischman, TJ Brady and R Weissleder
Department of Radiology, Massachusetts General Hospital and Harvard Medical School, Charlestown 02129, USA.

OBJECTIVE: To obtain initial data on the safety and efficacy of a novel polymeric, synthetic blood pool contrast agent [O- monomethoxypoly(ethylene glycol)-O'succinyl]poly(N-epsilon-L-lysyl [99mTc]diethylenetriamine pentaacetate monoamide, we performed a preclinical evaluation and phase 1 clinical trial under an investigator- sponsored investigational new drug application. MATERIALS AND METHODS: Methoxypoly(ethylene glycol)ethylenetriaminopentaacetic acid was formulated into a kit containing the polymer, stannous chloride, and a buffer. Kits were stored in frozen form for subsequent labeling with technetium-99m. Acute and subacute toxicity studies were carried out in rats and rabbits. Healthy human volunteers (n = 6) were then enrolled in a prospective, open-label phase 1 clinical study. RESULTS: Animal studies showed no signs of acute or subacute toxicity at doses 280 times the proposed dose for humans. In the clinical trial with humans, no significant abnormalities of laboratory values, ECG findings, or hemodynamic parameters were seen. One volunteer experienced facial flushing and palpitations. Four volunteers showed typical blood pool biodistribution, with a blood half-life of 20.6 +/- 2.3 hr. At 24 hr after administration, 22.1% +/- 2.5% of the injected dose had been excreted through the kidneys. Two other volunteers showed a different biodistribution (primarily to liver and spleen), presumably associated with labeling instability. CONCLUSION: Synthetic methoxypoly(ethylene glycol)-grafted polymers can have long circulation times in humans. Pharmaceuticals based on such polymers are expected to have clinical applications in cardiovascular imaging, gastrointestinal bleeding studies, and capillary leak imaging.
CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				X. Montet, J.-L. Figueiredo, H. Alencar, V. Ntziachristos, U. Mahmood, and R. Weissleder Tomographic Fluorescence Imaging of Tumor Vascular Volume in Mice Radiology, March 1, 2007; 242(3): 751 - 758. [Abstract] [Full Text] [PDF]

				G. J. Kelloff, K. A. Krohn, S. M. Larson, R. Weissleder, D. A. Mankoff, J. M. Hoffman, J. M. Link, K. Z. Guyton, W. C. Eckelman, H. I. Scher, et al. The Progress and Promise of Molecular Imaging Probes in Oncologic Drug Development Clin. Cancer Res., November 15, 2005; 11(22): 7967 - 7985. [Abstract] [Full Text] [PDF]

				Y. Tang, M. Kim, D. Carrasco, A. L. Kung, L. Chin, and R. Weissleder In vivo Assessment of RAS-Dependent Maintenance of Tumor Angiogenesis by Real-time Magnetic Resonance Imaging Cancer Res., September 15, 2005; 65(18): 8324 - 8330. [Abstract] [Full Text] [PDF]

				K. Shah, C.-H. Tung, C.-H. Chang, E. Slootweg, T. O'Loughlin, X. O. Breakefield, and R. Weissleder In Vivo Imaging of HIV Protease Activity in Amplicon Vector-transduced Gliomas Cancer Res., January 1, 2004; 64(1): 273 - 278. [Abstract] [Full Text] [PDF]

				U. Mahmood and R. Weissleder Near-Infrared Optical Imaging of Proteases in Cancer Mol. Cancer Ther., May 1, 2003; 2(5): 489 - 496. [Abstract] [Full Text] [PDF]

				C. Bremer, M. Mustafa, A. Bogdanov Jr, V. Ntziachristos, A. Petrovsky, and R. Weissleder Steady-State Blood Volume Measurements in Experimental Tumors with Different Angiogenic Burdens--A Study in Mice Radiology, January 1, 2003; 226(1): 214 - 220. [Abstract] [Full Text] [PDF]

				C.-H. Tung, U. Mahmood, S. Bredow, and R. Weissleder In Vivo Imaging of Proteolytic Enzyme Activity Using a Novel Molecular Reporter Cancer Res., September 1, 2000; 60(17): 4953 - 4958. [Abstract] [Full Text]